This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Find 'Strong Buy' Stocks Near their Highs for February
by Benjamin Rains
Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February...
Zacks.com featured highlights MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical
by Zacks Equity Research
MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength Amid January Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.
Lift Portfolio Value With These 5 High Earnings Yield Picks
by Rimmi Singhi
RGA, JBL, LBRT, CGAU and COLL are a few high earnings yield value stocks that could be good additions to your portfolio now.
Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Relay Therapeutics, Inc. (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
COLL vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids
by Zacks Equity Research
A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
by Zacks Equity Research
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
Actinium (ATNM) Up on Commercialization Deal With Immedica
by Zacks Equity Research
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines
by Zacks Equity Research
Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.
FDA Finds Deficiencies in Myovant (MYOV), Pfizer's Myfembree sNDA
by Zacks Equity Research
Though the FDA identified deficiencies in Myovant's (MYOV) Myfembree sNDA for managing endometriosis-associated pain, a final decision on the application is yet to be communicated.